Aegerion Pharmaceuticals (NASDAQ:AEGR), According to the latest information the short interest in Aegerion Pharmaceuticals, Inc. plummeted by 4.6% or 247,285 shares. The final shorts are 18.1% of the total floated shares. The positions dropped from 5,426,526 shares on May 31,2016 to 5,179,241 on June 15,2016. According to the per-day average trading of 1,843,211 shares, the days to cover are 3. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Aegerion Pharmaceuticals (NASDAQ:AEGR): The stock opened at $1.58 on Friday but the bulls could not build on the opening and the stock topped out at $1.69 for the day. The stock traded down to $1.52 during the day, due to lack of any buying support eventually closed down at $1.54 with a loss of -7.78% for the day. The stock had closed at $1.67 on the previous day. The total traded volume was 3,046,851 shares.
The company shares have dropped -91.47% from its 1 Year high price. On Jul 28, 2015, the shares registered one year high at $20.45 and the one year low was seen on Jun 14, 2016. The 50-Day Moving Average price is $1.76 and the 200 Day Moving Average price is recorded at $4.96.
Aegerion Pharmaceuticals (NASDAQ:AEGR) has tumbled 8.88% during the past week and has dropped 15.39% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 7.36%. Aegerion Pharmaceuticals (NASDAQ:AEGR) has underperformed the index by 12.82% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Companys products include Juxtapid (lomitapide) and MYALEPT (metreleptin). Lomitapide is a small molecule microsomal triglyceride transfer protein, which is marketed under the brand name Juxtapid (lomitapide) capsules (Juxtapid) in the United States as an adjunct to a low-fat diet and other lipid-lowering treatments. Lomitapide was also approved in the European Union under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA), as a treatment for homozygous familial hypercholesterolemia (HoFH) in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor and is available as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.